Epidermal growth factor receptor in tumor angiogenesis

被引：147
作者：
Ellis, LM [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2004年 / 18卷 / 05期
关键词：
D O I：
10.1016/j.hoc.2004.06.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This article focuses on the preclinical evidence for activation of the epidermal growth factor receptor (EGFR) in promoting angiogenesis and the efficacy of anti-EGFR agents in inhibiting angiogenesis and tumor growth.
引用
收藏
页码：1007 / +
页数：16
相关论文
共 82 条
[1]  
[Anonymous], P AM SOC CLIN ONCOL
[2]  
Baker CH, 2002, CANCER RES, V62, P1996
[3]   Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines [J].
Bancroft, CC ;
Chen, Z ;
Yeh, J ;
Sunwoo, JB ;
Yeh, NT ;
Jackson, S ;
Jackson, C ;
Van Waes, C .
INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (04) :538-548
[4]   ZD1839 ('Iressa')1,2 as an anticancer agent [J].
Baselga, J ;
Averbuch, SD .
DRUGS, 2000, 60 (Suppl 1) :33-40
[5]   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].
Baselga, J ;
Pfister, D ;
Cooper, MR ;
Cohen, R ;
Burtness, B ;
Bos, M ;
D'Andrea, G ;
Seidman, A ;
Norton, L ;
Gunnett, K ;
Falcey, J ;
Anderson, V ;
Waksal, H ;
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914
[6]  
Bouma-ter Steege JCA, 2001, CRIT REV EUKAR GENE, V11, P319
[7]  
Bruns CJ, 2000, CLIN CANCER RES, V6, P1936
[8]  
Bruns CJ, 2000, CANCER, V89, P488, DOI 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.3.CO
[9]  
2-O
[10]  
BURTNESS BA, 2002, P AM SOC CLIN ONCOL, V21
123456789